Unknown

Dataset Information

0

SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy.


ABSTRACT: Molecular mechanisms underlying adaptive targeted therapy resistance in pancreatic ductal adenocarcinoma (PDAC) are poorly understood. Here, we identify SETD5 as a major driver of PDAC resistance to MEK1/2 inhibition (MEKi). SETD5 is induced by MEKi resistance and its deletion restores refractory PDAC vulnerability to MEKi therapy in mouse models and patient-derived xenografts. SETD5 lacks histone methyltransferase activity but scaffolds a co-repressor complex, including HDAC3 and G9a. Gene silencing by the SETD5 complex regulates known drug resistance pathways to reprogram cellular responses to MEKi. Pharmacological co-targeting of MEK1/2, HDAC3, and G9a sustains PDAC tumor growth inhibition in vivo. Our work uncovers SETD5 as a key mediator of acquired MEKi therapy resistance in PDAC and suggests a context for advancing MEKi use in the clinic.

SUBMITTER: Wang Z 

PROVIDER: S-EPMC8187079 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

2020-05-06 | GSE142046 | GEO
| PRJNA595697 | ENA
| S-EPMC4565533 | biostudies-literature
| S-EPMC3631697 | biostudies-other
| S-ECPF-GEOD-39418 | biostudies-other
2021-12-31 | GSE156302 | GEO
| S-EPMC3220622 | biostudies-literature
| S-EPMC4050702 | biostudies-literature
2018-05-15 | GSE106321 | GEO
| S-EPMC7116658 | biostudies-literature